Detailed performance report for PDS BIOTECH covering Q2 2025. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.
PDS Biotech reported a net loss of $9.4 million ($0.21 per share) for Q2 2025, an increase from the $8.3 million ($0.23 per share) loss in Q2 2024, primarily due to higher net interest expenses. Operating expenses decreased to $7.6 million (from $8.7 million last year), driven by lower personnel costs and professional fees, offset by rising manufacturing costs. The company’s cash balance was $31.9 million as of June 30, 2025, down from $41.7 million at year-end 2024.
PDS Biotech is focused on advancing its VERSATILE-003 Phase III clinical trial targeting HPV16-positive head and neck cancer, which represents a critical unmet medical need. The company plans to leverage promising survival and tolerability data from its VERSATILE-002 Phase II trial to drive enrollment in VERSATILE-003. Additionally, PDS Biotech has expanded its metastatic colorectal cancer trial (PDS01ADC) to Stage 2 following positive results, with recruitment expected to conclude by Q4 2025. The company is also advancing preclinical development of a universal flu vaccine in collaboration with NIAID.
HPV16-positive head and neck cancer is becoming increasingly prevalent, projected to be the most common type by the mid-2030s in the U.S. and Europe. Current clinical guidelines do not differentiate between HPV-positive and HPV-negative cancers, presenting an opportunity for targeted therapies. Oncology experts are emphasizing the need for treatments that offer improved survival, tolerability, and quality of life, which aligns with PDS Biotech’s strategic focus.
This concise summary captures the critical insights from PDS Biotech’s Q2 2025 earnings call. Let me know if additional details are needed!
Access the official earnings call transcript for PDS-BIOTECH 2025 Q2. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.